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Not all SCN1A epileptic encephalopathies
are Dravet syndrome
Early profound Thr226Met phenotype
ABSTRACT
Objective: To define a distinct SCN1A developmental and epileptic encephalopathy with early
onset, profound impairment, and movement disorder.
Methods: A case series of 9 children were identified with a profound developmental and epileptic
encephalopathy and SCN1A mutation.
Results:We identified 9 children 3 to 12 years of age; 7 were male. Seizure onset was at 6 to 12
weeks with hemiclonic seizures, bilateral tonic-clonic seizures, or spasms. All children had pro-
found developmental impairment and were nonverbal and nonambulatory, and 7 of 9 required
a gastrostomy. A hyperkinetic movement disorder occurred in all and was characterized by dys-
tonia and choreoathetosis with prominent oral dyskinesia and onset from 2 to 20 months of age.
Eight had a recurrent missense SCN1A mutation, p.Thr226Met. The remaining child had the
missense mutation p.Pro1345Ser. The mutation arose de novo in 8 of 9; for the remaining case,
the mother was negative and the father was unavailable.
Conclusions: Here, we present a phenotype-genotype correlation for SCN1A. We describe a dis-
tinct SCN1A phenotype, early infantile SCN1A encephalopathy, which is readily distinguishable
from the well-recognized entities of Dravet syndrome and genetic epilepsy with febrile seizures
plus. This disorder has an earlier age at onset, profound developmental impairment, and a distinc-
tive hyperkinetic movement disorder, setting it apart from Dravet syndrome. Remarkably, 8 of 9
children had the recurrent missense mutation p.Thr226Met. Neurology® 2017;89:1035–1042
GLOSSARY
GEFS1 5 genetic epilepsy with febrile seizures plus.
The finding of de novo SCN1A mutations in Dravet syndrome was paradigm shifting in our
understanding of the etiology of the developmental and epileptic encephalopathies.1,2 Less
commonly, inherited SCN1A mutations occur in the self-limiting familial epilepsy syndrome
of genetic epilepsy with febrile seizures plus (GEFS1).3 Missense and truncation mutations are
found in approximately equal frequency in Dravet syndrome, while GEFS1 is largely associated
with missense mutations.4 Despite .1,200 reported SCN1A mutations and most patients
having novel mutations, there are no clear phenotype-genotype correlations.
We have identified a distinctive SCN1A developmental and epileptic encephalopathy that is
far more severe than Dravet syndrome and is associated with a recurrent missense mutation. It is
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Table Clinical features and investigations of children with early infantile SCN1A encephalopathy
Case (sex/age)
1 (M/8 y) 2 (M/6 y) 3 (M/9 y)5 4 (M/8 y)5 5 (M/9 y) 6 (M/10 y)2 7 (F/1 y) 8 (F/3 y) 9 (M/12 y)6
Mutation c.677C.T,
p.Thr226Met de
novo
c.677C.T,
p.Thr226Met de novo
c.677C.T,
p.Thr226Met;
mother negative,
father unknown
c.677C.T,
p.Thr226Met de novo
c.677C.T,
p.Thr226Met de
novoa
c.677C.T,
p.Thr226Met de
novo
c.677C.T,
p.Thr226Met de
novo
c.677C.T,
p.Thr226Met de novo
c.4033C.T,
p.Pro1345Ser de
novo
Sz onset age
(offset)
12 wk; HC-SE 9 wk; HC-SE 9 wk; HC-SE 8 wk; TC-SE 11 wk; TC (8 y) 8 wk; HC (died–10
y, SUDEP)
12 WK; HC;
possible ES–8 wk
6 wk; ES 8 wk; HC; possible
ES–6 wk
Other Sz onset
age
18 mo–TC, T; 2 y–
Ab; 3 y–M; ES; 5 y–F,
NCS
3 mo–TC, M, F; 2 y–
ES, NCS
18 mo–TC; 4 y–T,
At; 7 y–NCS
9 wk–HC; 21 mo–M; 3
y–Ab, NCS; 5 y–MA
7 y–T 9 mo–TC, F, SE;
M, 13 mo–T
6 mo–SE; 12 mo–
M, TC, F
10 wk–HC, F; 6 mo–
TC, SE; 7 mo–M
10 wk–TC, ES; 6 mo–
M; 1 y–Ab; 2 y–SE, F;
5 y–T
Sz triggers M: sound and
wakening
Excitement and water;
ES: feeding and
drinking
T: fever and feeding Fever, illness, and hot
environment
Bowel movements Fever Fever, excitement,
and
overstimulation
Fever T: excitement, noise,
light, and hot
environment
MD onset 11 mo 3 mo 9 wk 20 mo ,6 mo 9 mo 4 mo 11 mo 11 mo
MD description Hyperkinesis;
dystonia;
choreoathetosis
limbs and orofacial
Dystonia;
choreoathetosis
including orofacial;
exacerbated by
excitement and
bathing; severely
tremulous on waking
Continuous
myoclonic
movements,
especially orofacial;
exacerbated by
visual stimuli;
tremulous on
waking
Dystonia;
choreoathetosis;
continuous unilateral
horizontal nystagmus;
myoclonic movements;
profound ataxia
Hyperkinesis,
especially orofacial;
myoclonic
movements;
dystonia;
nystagmus;
stereotypies;
exacerbated by
tiredness and
excitement
Continuous
multifocal
myoclonic
movements;
nystagmus,
vertical and
horizontal
Continuous
hyperkinesis and
chorea;
exacerbated by
overstimulation
Continuous
choreoathetosis,
multifocal myoclonic
movements;
exacerbated by
tiredness, drowsiness,
and waking
Hyperkinesis;
choreoathetosis;
myoclonic
movements,
especially orofacial
Age DD noted 4 mo 9 wk 9 wk 9 wk 6 wk 9 wk 3 mo 10 wk 8 wk
Development
outcome
NV, communicates
with facial gestures,
smiles and sounds;
NA, G-tube
NV but vocalizes, NA–
stands with support
NV, NA–sits with
support, G-tube
NV, NA–stands with
support, G-tube
NV, NA–sits with
support
NV–smiles, NA, G-
tube
NV, NA, G-tube NV, NA, G-tube Only 2 single words,
NA, G-tube
Medication trials KD, PHT, LEV, TPM,
NZP, CZP, PB
VGB, CZP, VPA,
steroids, PB, LTG,
LEV, CLB, TPM
PB, CBZ, VPA, CLB,
KD
PB, PHT, TPM, VPA,
CZP, RFM, ETX, AZD,
steroids, LEV, STP,
CBD, KD
VPA, LTG, PB, PHT,
CLB, TPM, LEV
PB, VPA, CBZ,
PHT, ACTH, CLB,
TPM, CZP, LEV,
STP
PB, OX, GP, LEV,
CBD, KD, TPM,
CLB, VPA
PB, PRD, ACTH, TPM,
LEV, KD, CZP, CLB,
DZP
CBZ, PB, VGB, VPA,
PHT, CLB, LTG,
steroids, LEV, KD,
cannabis oils
Examination Hypertelorism, high
forehead, small
mouth; axial
hypotonia; variable
limb tone;
kyphoscoliosis
Axial hypotonia;
variable limb tone
Hypotonia Hypotonia Microcephaly; axial
hypotonia; variable
limb tone with brisk
reflexes; scoliosis
Spasmus nutans;
tone increased at
3 mo but
hypotonic later
Axial hypotonia;
hypertonia of limbs
Hypotonia Axial hypotonia;
variable limb tone
Continued
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characterized by early infantile seizure onset,
profound intellectual disability, and a severe
hyperkinetic movement disorder. This recur-
rent SCN1A mutation shows clear genotype-
phenotype correlation.
METHODS Case 1 presented with an early infantile profound
developmental and epileptic encephalopathy. Because he had
hemiclonic seizures, the senior author (I.E.S.) requested SCN1A
testing that revealed a de novo missense variant (Thr226Met).
Because this phenotype was distinctive, we interrogated the Epi-
lepsy Genetics Database at the University of Melbourne, which
contained 981 individuals with solved and unsolved developmen-
tal and epileptic encephalopathies tested for SCN1A mutations.
We searched for children with de novo SCN1A variants who
presented at ,4 months of age and had a movement disorder.
All identified patients were included. This identified 3 additional
cases: cases 2 and 6 with the Thr226Met variant and case 9 with
the Pro1345Ser variant. Because 3 of the 4 cases had the
Thr226Met variant, we searched our database and the literature
for other cases with this variant and attempted to contact the
authors for more phenotypic information. This resulted in an
additional 2 cases (cases 3 and 4).5 The final 3 cases (cases 5, 7,
and 8) were recruited when collaborators asked the first (L.G.S.)
and senior (I.E.S.) authors about the role of the de novo SCN1A
Thr226Met variant that they had identified in their patients who
presented with an atypical phenotype for Dravet syndrome.
Epilepsy and medical history, neurologic examination,
and MRI and EEG data were obtained for each patient.
SCN1A mutations were identified by clinical or research test-
ing; segregation testing in parents was possible for 8
individuals.
Standard protocol approvals, registrations, and patient
consents. The Austin Health Human Research Ethics Commit-
tee and the New Zealand Health and Disability Ethics Commit-
tees approved the study. Informed consent was obtained for each
patient from the parents or legal guardian. In addition, specific
written consent for authorization of video use was obtained for
the 3 cases in the video.
RESULTS We identified 9 (7 boys) unrelated chil-
dren 3 to 12 years of age (table). They presented with
seizures at a mean age of 9 weeks (range 6–12 weeks)
with predominantly hemiclonic seizures (n 5 6) but
also with bilateral tonic-clonic seizures (followed 1
week later by hemiclonic seizures in 1 patient) or
epileptic spasms. All children developed tonic-clonic
seizures by 18 months. Eight had episodes of con-
vulsive status epilepticus with onset between 8 weeks
and 2 years (table). Myoclonic seizures (7 of 9), tonic
seizures (5 of 9), and spasms (5 of 9) were also seen.
Epilepsy was refractory to multiple antiepileptic
medications in all cases, although 1 child became
seizure free at 8 years. Five children had seizures
associated with fever or illness, and 2 children had
seizures exacerbated by high environmental temper-
ature. There were no reports of vaccination triggering
seizures. Other seizure triggers included auditory
stimuli (2), excitement (3), feeding (2), and bowel
movements (1).
T
ab
le
C
on
ti
nu
ed C
as
e
(s
ex
/a
g
e)
1
(M
/8
y)
2
(M
/6
y)
3
(M
/9
y)
5
4
(M
/8
y)
5
5
(M
/9
y)
6
(M
/1
0
y)
2
7
(F
/1
y)
8
(F
/3
y)
9
(M
/1
2
y)
6
E
E
G
4
m
o,
9
m
o,
1
1
m
o,
4
y,
an
d
6
y;
M
F
D
an
d
sl
ow
2
,2
.5
,a
nd
4
m
o:
N
;2
an
d
3
y:
M
F
D
an
d
sl
ow
;3
y:
br
ie
f
bu
rs
ts
of
rh
yt
hm
ic
fa
st
bi
te
m
po
ra
la
ct
iv
it
y
tr
ig
ge
re
d
by
th
e
pl
ac
em
en
t
of
fo
od
in
m
ou
th
3
m
o:
F
D
an
d
sl
ow
;
1
,1
.5
,4
.5
,a
nd
7
y:
M
F
D
an
d
sl
ow
1
0
,1
4
,1
9
,2
0
m
o
an
d
2
y:
M
F
D
,G
S
W
,a
nd
sl
ow
;5
y:
at
yp
ic
al
G
S
W
,E
S
E
S
;6
y:
M
F
D
,
E
S
E
S
,a
nd
sl
ow
1
4
m
o:
F
D
;2
an
d
8
y:
M
F
D
an
d
sl
ow
9
w
k:
F
D
;1
5
m
o:
M
F
D
an
d
sl
ow
;2
y:
P
S
W
an
d
sl
ow
;
3
y:
M
FD
,p
er
io
ds
of
at
te
nu
at
io
n
8
w
k,
1
2
w
k,
an
d
6
m
o:
N
;1
5
m
o
an
d
5
y:
M
F
D
an
d
sl
ow
;
1
0
y:
G
S
W
1
0
an
d
1
2
w
k:
M
FD
an
d
sl
ow
;9
m
o:
F
D
;1
1
an
d1
2
m
o:
M
F
D
an
d
sl
ow
;2
1
m
o:
E
S
E
S
1
an
d
1
.5
y:
N
;2
y:
M
F
D
an
d
sl
ow
;2
.5
y:
G
S
W
an
d
sl
ow
;3
y:
M
F
D
an
d
sl
ow
;5
y:
bi
fr
on
ta
ls
pi
ke
an
d
w
av
e
in
ru
ns
an
d
sl
ow
;1
0
y:
M
F
D
an
d
sl
ow
M
R
I
S
m
al
lh
ip
po
ca
m
pi
,
de
ve
lo
pe
d
L
H
S
;
dy
sm
or
ph
ic
co
rp
us
ca
llo
su
m
;
pr
og
re
ss
iv
e
w
hi
te
m
at
te
r
vo
lu
m
e
at
ro
ph
y
S
m
al
lh
ip
po
ca
m
pi
at
1
y;
de
ve
lo
pe
d
bi
la
te
ra
l
en
la
rg
ed
hi
pp
oc
am
pi
,
L
m
al
ro
ta
te
d
L
te
m
po
ra
lf
os
sa
ar
ac
hn
oi
d
cy
st
P
in
ea
lc
ys
t
N
S
m
al
lh
ip
po
ca
m
pi
,
L
hi
pp
oc
am
pu
s
m
al
ro
ta
te
d;
pr
og
re
ss
iv
e
w
hi
te
m
at
te
r
at
ro
ph
y
G
en
er
al
iz
ed
at
ro
ph
y;
bi
la
te
ra
l
sm
al
lh
ip
po
ca
m
pi
G
en
er
al
iz
ed
at
ro
ph
y;
R
m
es
ia
lt
em
po
ra
l
sc
le
ro
si
s;
te
m
po
ra
l
ar
ac
hn
oi
d
cy
st
s
S
m
al
lh
ip
po
ca
m
pi
;
dy
sm
or
ph
ic
co
rp
us
ca
llo
su
m
A
bb
re
vi
at
io
ns
:A
b
5
ab
se
nc
e
se
iz
ur
e;
A
C
TH
5
ad
re
no
co
rt
ic
ot
ro
pi
c
ho
rm
on
e;
A
t
5
at
on
ic
se
iz
ur
e;
A
Z
D
5
ac
et
az
ol
am
id
e;
C
B
D
5
ca
nn
ab
id
io
l;
C
B
Z
5
ca
rb
am
az
ep
in
e;
C
LB
5
cl
ob
az
am
;C
Z
P
5
cl
on
az
ep
am
;D
D
5
de
ve
lo
pm
en
ta
ld
el
ay
;D
Z
P
5
di
az
ep
am
;E
S
5
ep
ile
pt
ic
sp
as
m
s;
E
S
E
S
5
el
ec
tr
ic
st
at
us
ep
ile
pt
ic
us
in
sl
ee
p;
E
TX
5
et
ho
su
xa
m
id
e;
F
5
ot
he
r
fo
ca
ls
ei
zu
re
;F
D
5
fo
ca
le
pi
le
pt
if
or
m
di
sc
ha
rg
es
;G
P
5
ga
ba
pe
nt
in
;
G
S
W
5
ge
ne
ra
liz
ed
sp
ik
e
an
d
sl
ow
w
av
e;
G
-t
ub
e
5
ga
st
ro
st
om
y
tu
be
;H
C
5
he
m
ic
lo
ni
c
se
iz
ur
e;
H
S
5
hi
pp
oc
am
pa
ls
cl
er
os
is
;K
D
5
ke
to
ge
ni
c
di
et
;L
E
V
5
le
ve
ti
ra
ce
ta
m
;L
TG
5
la
m
ot
ri
gi
ne
;M
5
m
yo
cl
on
ic
se
iz
ur
e;
M
A
5
m
yo
cl
on
ic
ab
se
nc
e
se
iz
ur
e;
M
D
5
m
ov
em
en
t
di
so
rd
er
;
M
F
D
5
m
ul
ti
fo
ca
l
ep
ile
pt
if
or
m
di
sc
ha
rg
es
;
N
5
no
rm
al
;
N
A
5
no
na
m
bu
la
to
ry
;
N
C
S
5
no
nc
on
vu
ls
iv
e
st
at
us
ep
ile
pt
ic
us
;
N
V
5
no
nv
er
ba
l;
N
Z
P
5
ni
tr
az
ep
am
;
O
X
5
ox
ca
rb
az
ep
in
e;
P
B
5
ph
en
ob
ar
bi
to
ne
;
P
H
T
5
ph
en
yt
oi
n;
P
R
D
5
pr
ed
ni
so
lo
ne
;
P
S
W
5
po
ly
sp
ik
e
an
d
w
av
e;
R
F
M
5
ru
fi
na
m
id
e;
S
E
5
st
at
us
ep
ile
pt
ic
us
;
S
TP
5
st
ir
ip
en
to
l;
S
U
D
E
P
5
su
dd
en
un
ex
pl
ai
ne
d
de
at
h
in
ep
ile
ps
y;
S
z
5
se
iz
ur
e;
T
5
to
ni
c
se
iz
ur
e;
TC
5
to
ni
c-
cl
on
ic
se
iz
ur
e;
TP
M
5
to
pi
ra
m
at
e;
V
G
B
5
vi
ga
ba
tr
in
;V
P
A
5
va
lp
ro
at
e.
a
S
C
N
1
A
m
ut
at
io
n
id
en
ti
fi
ed
vi
a
th
e
D
D
D
S
tu
dy
G
ro
up
.
Neurology 89 September 5, 2017 1037
Initial development was considered normal by all
parents, who gave reports of normal early develop-
mental milestones. Delay was evident, however, by
6 to 16 weeks. At last review (range 3–12 years), 8
children were nonverbal, and 1 child spoke 2 single
words. All were nonambulatory, and 7 required
enteral feeding. The children had periods of regres-
sion or developmental plateauing resulting in pro-
found intellectual disability. One child died at 10
years of sudden unexplained death in epilepsy.
All patients had a prominent movement disorder
that developed within the first 2 years of life (9
weeks–20 months). Initially, they presented with
subtle, low-amplitude myoclonic jerks. Over time,
a hyperkinetic movement disorder comprising cho-
rea, dystonia, and low-amplitude myoclonic move-
ments was noted, particularly evident in the
orofacial area (video at Neurology.org). Although
not always present, the movement disorder was per-
sistent and exacerbated on awakening and excite-
ment. The abnormal movements were not seen
during sleep. EEG recordings showed no epileptiform
activity with these movements.
Eight of our 9 cases were trialed on antiepileptic
drugs that could induce or exacerbate movement dis-
orders or myoclonic seizures such as vigabatrin or
sodium channel blockers (e.g., phenytoin, carbamaze-
pine, oxcarbazepine, lamotrigine). In several cases,
these drugs were begun well after the movement dis-
order had been recognized. Subsequent
discontinuation of the medication had no effect on
the movement disorder. There was also no clear exac-
erbation of their seizures with these medications;
however, their seizures were so frequent that it may
have been difficult to assess.
Neuroimaging was normal or showed nonspecific
abnormalities. Four children had developmentally
abnormal hippocampi; 2 had dysmorphic corpus cal-
losal; and 2 had progressive white matter loss (table
and figure). EEGs were initially normal in 3 children,
but by 2 years of age, all had developed multifocal
discharges and diffuse background slowing. Four chil-
dren had generalized spike and slow wave or poly-
spike and slow wave.
All patients had SCN1A mutations; 8 were con-
firmed de novo. The mother of case 3 was negative,
and the father was unavailable. Cases 1, 2, and 9 were
identified on molecular inversion probe–targeted re-
sequencing6; cases 3, 4, and 8 were identified on
clinical panels; case 5 was identified on whole-exome
sequencing; and cases 6 and 7 were identified by
SCN1A sequencing. No additional likely pathogenic
variants were found in other genes in the cases that
had targeted resequencing, clinical panels, or whole-
exome sequencing. Eight children had the same mis-
sense mutation, p.Thr226Met, resulting from
c.677C.T in exon 5. In silico tools suggested that
it was deleterious (Grantham D 5 81, Polyphen2 5
1, SIFT 5 0, GERP 5 5.77, CADD 5 20.5). The
ninth child had a de novo missense mutation,
Figure MRI in children with early infantile SCN1A encephalopathy
(A–C) Coronal views in case 1 (3 years of age), case 9 (5 years of age), and case 2 (1 year of age) show bilateral small
hippocampi. (A) Case 1 developed left hippocampal sclerosis. (C) Case 2 has a malrotated left hippocampus. (D, F) Axial T2
and coronal T1 images of case 9 show (D) normal white matter volume at 2months of age with (F) moderately severe volume
loss at 2 years. (E) Coronal views of the hippocampi at 2 months show bilateral small hippocampi with left hippocampal
malrotation.
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p.Pro1345Ser (c.4033C.T), which was pathogenic
on in silico testing (Grantham D5 74, Polyphen25
1, SIFT 5 0, GERP 5 5.42, CADD 5 23.7).
CASE HISTORIES Case 1. Case 1 is an 8-year-old
boy who presented at 12 weeks of age with afebrile
hemiclonic status epilepticus lasting 30 minutes.
Frequent pharmacoresistant hemiclonic seizures last-
ing 1 minute to 6 hours occurred daily. The lateral-
ization of the clonic activity varied and occasionally
migrated from 1 upper limb, to hemiclonic, to both
lower limbs, to hemiclonic on the other side. Bilateral
tonic-clonic and tonic seizures began at 18 months,
absence seizures at 2 years, and myoclonic seizures or
epileptic spasms at 3 years. By 5 years, he developed
focal impaired awareness seizures that could progress
to nonconvulsive status epilepticus lasting hours,
frequent nocturnal tonic seizures, and weekly series of
epileptic spasms. Seizures were triggered by waking
but not by illness or fever. He has had multiple
hospital admissions for status epilepticus and poor
seizure control, the longest a 3-month admission at
18 months. Trials of phenobarbital, phenytoin, ni-
trazepam, clonazepam, levetiracetam, and topiramate
were ineffective. The ketogenic diet was initiated at 4
years and resulted in improved control with cessation
of myoclonic seizures. By 8 years, he was on ketogenic
diet monotherapy and continued to have weekly
tonic-clonic, focal impaired awareness, and tonic
seizures in sleep and required admission every few
months.
From birth, he had significant early feeding diffi-
culties. Developmental milestones were otherwise
normal with good head control, smiling, and fixing
and following by 6 weeks. From 4 months, his devel-
opment plateaued and fluctuated over the next few
years with regression between 3 and 4 years. He lost
eye contact, smiling, vocalization, head control, and
the ability to roll over. He required a gastrostomy
for feeding. When he was initiated on the ketogenic
diet at 4.5 years, he had a marked improvement in
alertness and developmental gains. At 8 years, he
smiled, laughed, and vocalized vowel sounds but
was nonverbal. He did not feed orally. He was able
to roll over but could not sit.
He developed a hyperkinetic movement disorder
by his first birthday consisting of choreiform move-
ments including the orofacial area, dystonic posturing
of the upper and lower limbs, and myoclonus without
EEG correlate (video). Video monitoring at 16
months confirmed that all the abnormal movements
did not have an epileptiform correlate. He has normal
tone in his limbs with reduced truncal tone. He has
hypertelorism, a high forehead, a small mouth, a nor-
mal head circumference, and a mild kyphoscoliosis.
EEGs from 4 months showed multifocal epileptiform
activity with background slowing. At 4 months, MRI
brain revealed bilateral small hippocampi with a dys-
morphic corpus callosum. By 3 years, he had devel-
oped left hippocampal sclerosis and progressive
white matter atrophy (figure, A).
Case 2. Case 2 is a 6-year-old boy who presented at 9
weeks with 5 independent afebrile right and left
hemiclonic seizures lasting from 1 to 20 minutes over
a 2-hour period that were treated with buccal and
intravenous midazolam and intravenous phenytoin.
Occasional hemiclonic seizures continued despite the
introduction of phenobarbital and topiramate. He
developed myoclonic, focal impaired awareness and
bilateral tonic-clonic seizures by 13 weeks. The seiz-
ures were not associated with fever but were more
likely to occur on waking. At 13 weeks, he developed
a periodic movement disorder initially lasting 10 to
30 minutes consisting of choreoathetosis, dystonia,
and small-amplitude myoclonic jerks, which his pa-
rents called “dancing.” This was triggered by waking
and excitement, particularly bathing. His movement
disorder progressed over the next 18 months so that
by 2 years it occurred almost continuously, although
it settled in sleep. He did, however, have massive
myoclonic jerks without EEG correlate on awaken-
ing. His epilepsy was refractory to sodium valproate,
lamotrigine, and levetiracetam. From 2 years, he had
infrequent episodes of focal nonconvulsive status
epilepticus, characterized by loss of awareness, eye
deviation, and facial twitching, lasting up to 2 hours.
The EEG showed high-voltage rhythmic focal delta
in the centro-parietal region. At 2.5 years, he devel-
oped flexor epileptic spasms when eating or drinking.
The spasms occurred every 10 to 20 seconds for
3 minutes shortly after food or liquid was put in his
mouth and interfered with his ability to chew and
swallow. The spasms were controlled for 2 months
but then relapsed and are ongoing. By 4 years, the
massive myoclonic jerks were awakening him over-
night, which triggered his movement disorder and
prevented him from sleeping, posing a major problem
for the family’s quality of life.
His development was normal at 9 weeks; he smiled
and fixed and followed by 6 weeks. Within a week of
seizure onset, he regressed with loss of visual fixation
and head control. By 5 months, he was rolling over,
and by 8 months, he was sitting and finger-feeding.
After 9 months, his development plateaued with
a period of regression at 2 years. At 6 years, he vocalizes
but is nonverbal, nor can he sit or walk independently.
On examination, he was not dysmorphic and had
almost continuous choreiform movements involving
the limbs and orofacial region (video). His limb tone
was variable with axial hypotonia. Early EEGs
between 10 weeks and 4 months were normal, but
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multifocal epileptiform abnormalities had developed
by 2 years. MRI at 1 year showed bilateral small
hippocampi with left hippocampal malrotation
(figure, C).
DISCUSSION SCN1A is the most relevant epilepsy
gene. Despite considerable effort, no phenotype-
genotype correlation has been shown for the hun-
dreds of SCN1A mutations identified, with the
majority associated with Dravet syndrome and a small
proportion with GEFS1.4 Here, we show a pheno-
type-genotype correlation for SCN1A describing
a distinct SCN1A phenotype, early infantile SCN1A
encephalopathy, that is far more severe than Dravet
syndrome. We bring together novel cases and rean-
alyze the phenotype of reported cases with the
recurrent mutation to identify a distinctive entity of
early-onset developmental and epileptic encephalop-
athy with profound impairment and a prominent
movement disorder.
Early infantile SCN1A encephalopathy can be
readily distinguished from Dravet syndrome by sev-
eral features. It has a younger age at onset, beginning
at ,3 months compared with the typical seizure
onset age range of 4 to 15 months in Dravet syn-
drome. It is associated with profound developmental
impairment rather than the severe to mild intellectual
disability usually seen in Dravet syndrome. Infantile
movement disorders are not part of the Dravet phe-
notype, whereas our patients have a distinctive move-
ment disorder with choreoathetosis, dystonia, and
perioral hyperkinesia. Other features differentiating
early infantile SCN1A encephalopathy from Dravet
syndrome are epileptic spasms, which are not seen in
Dravet syndrome. Tonic seizures are described in
adults with Dravet syndrome but are not part of the
childhood phenotype.7
We describe that the Thr226Met mutation is
associated with a distinctive profound SCN1A
encephalopathy. Three of the 8 patients with
Thr226Met (cases 3, 4, and 6) have been previously
reported as having Dravet syndrome.2,5 Case 6 was
identified in 2007 in our large study delineating the
phenotypic spectrum of Dravet syndrome.2 Cases 3
and 4 were drawn from a 2014 study of sleep prob-
lems associated with SCN1A-confirmed Dravet syn-
drome,5 but the phenotype was not described in the
report. The phenotype, early infantile SCN1A
encephalopathy, was not yet recognized, and
Dravet-like features such as hemiclonic seizures led
to the diagnosis of Dravet syndrome. We have rean-
alyzed the phenotype of these patients, and all share
a homogeneous profound phenotype.
In addition, there are 2 further individuals re-
ported with the Thr226Met mutation.2,8 One is
a child described as having progressive myoclonus
epilepsy; however, the limited available clinical infor-
mation suggests that the phenotype of this child could
be consistent with early infantile SCN1A encephalop-
athy.8 Overlap between the movement disorder and
a progressive myoclonus epilepsy could be challeng-
ing to distinguish, especially given that the patient
was middle-aged at the time of review. The remaining
child presented with febrile status epilepticus at
6 months.2 However, she then developed extensor
epileptic spasms at 10 months, which would be
extraordinary for Dravet syndrome.7 This patient
was not reported to have a movement disorder, but
at 9 months, she had continuous myoclonic activity
diagnosed as nonconvulsive status epilepticus. This
could be a differential diagnosis of the movement
disorder in our patients, but overall, she had better
developmental progress. She also had an SCN9A variant
(p.W1538R) that may have modified her phenotype.9
Perhaps this caused loss of function of SCN9A, which
in some way modified the functional alteration due to
the SCN1A Thr226Met mutation.
The Thr226Met mutation is not the only SCN1A
mutation described at this specific codon. There are 2
reports of missense SCN1Amutations at codon c.677
that result in a different amino acid change to
Thr226Arg or Thr226Lys.10,11 Not enough clinical
information is provided in the reports to allow assess-
ment of whether these children have a similarly pro-
found phenotype.
A Japanese group has previously described a single
case of infantile epileptic encephalopathy with
a hyperkinetic movement disorder and hand stereoty-
pies associated with a different novel SCN1A muta-
tion.12,13 This Japanese child’s presentation sounds
like early infantile SCN1A encephalopathy in terms
of seizure onset age of 8 weeks; seizure types included
epileptic spasms, hemiclonic seizures, myoclonic seiz-
ures, generalized tonic-clonic seizures, and status epi-
lepticus, with profound impairment. The child also
had an early-onset severe hyperkinetic movement dis-
order and a different SCN1A missense mutation
(c.1264 G.T, p.Val422Leu) from that found in
our cohort.12,13
Despite there being .1,200 different reported
SCN1A mutations, only 18% of mutations are recur-
rent.4 Mutations associated with GEFS1 are more
likely to have a lower Grantham score than those that
cause Dravet phenotypes.4,14 Missense mutations in
the pore region lead to complete loss of function,
similar to haploinsufficiency, but are seen in both
Dravet syndrome (54%) and GEFS1 (31%).4 It is
therefore not usually possible to predict an individu-
al’s phenotype on the basis of their specific SCN1A
mutation. Here, however, we have identified a severe-
striking SCN1A phenotype, early infantile SCN1A
encephalopathy, that has a recurrent mutation at
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c.677 in almost all cases. Somewhat counterintui-
tively, this more severe phenotype is associated with
missense, rather than truncation, mutations.
There is increasing recognition of the overlap of
developmental epileptic encephalopathies and move-
ment disorders. Severe hyperkinetic (dystonia, chor-
eoathetosis, myoclonus) movements have been
described in a range of genetic encephalopathies
caused by SCN2A, SCN8A, FOXG1, STXBP1,
GNAO1, ARX, and DNM1, among others.12,15–17
Distinguishing a movement disorder from seizures
may affect therapeutic approaches in terms of when
to introduce antiepileptic therapy or other treatment
modalities.
There is a large group of early-onset developmen-
tal and epileptic encephalopathies defined by their
onset age of ,3 months, often not fitting within
a recognized epilepsy syndrome. These disorders have
been recently associated with a large, heterogeneous
range of genetic etiologies.18 They share many com-
mon features such as multiple seizure types, profound
to severe developmental delay, and movement disor-
ders. It is unlikely that the seizures or the treatment
per se cause the profound developmental impairment
or movement disorders, given that a similar spectrum
of seizure types with onset in later infancy or child-
hood does not have the same developmental sequelae.
For example, infants with the self-limited “benign”
early infantile seizure disorders may have frequent
seizures with an abnormal EEG but without the
long-term sequelae. Thus, we hypothesize that spe-
cific SCN1A mutations cause the overall phenotype.
However, it is conceivable that this complex
phenotype could be due to frequent seizures at
a younger age.
SCN2A and SCN8A encephalopathies both are
associated with gain-of-function mutations and
respond well to sodium channel blockers.15,16 Here,
we show that SCN1A also contributes to the severe
early infantile–onset developmental encephalo-
pathies, but we do not yet understand why this
recurrent mutation causes this profound phenotype.
It is interesting to speculate that it possibly is asso-
ciated with a gain of function akin to SCN2A and
SCN8A, but functional studies are required to prove
the mechanism of this devastating disorder.
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